NCT02098291View on ClinicalTrials.gov

An Open, Single-center Study to Determine the Antibody Repsonse to Gastrimmune and Its Safety and Tolerability in Patients With Advanced Pancreatic Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

April 30, 1999

Primary Completion Date

July 31, 2001

Study Completion Date

February 28, 2002

Conditions
Pancreatic Cancer
Interventions
DRUG

G17DT

Sponsors
All Listed Sponsors
lead

Cancer Advances Inc.

INDUSTRY

NCT02098291 - An Open, Single-center Study to Determine the Antibody Repsonse to Gastrimmune and Its Safety and Tolerability in Patients With Advanced Pancreatic Carcinoma | Biotech Hunter | Biotech Hunter